Gastro Health Research, formerly Consultants for Clinical Research (CCR), is a multi-specialty research facility involved in clinical research evaluating new investigational and existing medications, as well as medical devices. We believe that providing patients with alternatives for therapy, quality care, and education are important aspects of patient care.
Gastro Health Research is located in Alabama, Florida, Virginia, Maryland, Massachusetts, and Ohio and has conducted over 1,000 Gastroenterology and Liver clinical trials over the past 3 decades. The research department has participated in several pivotal trials that have led to approval and marketing of new treatments for Crohn’s Disease, Ulcerative Colitis, Irritable Bowel Syndrome, GERD, Hepatitis B and Hepatitis C, Duodenal and Gastric Ulcers and for the eradication of H. Pylori. A few of the notable landmark studies are the Remicade® (Infliximab) protocol (led by Dr. Michael Safdi) and Humira® (Adalimumab) protocol (led by Dr. Alan Safdi), both for the treatment of Crohn’s Disease, Ulcerative Colitis and Rheumatoid Arthritis. Dr. Mark Jonas and Ravi Ravinuthala have been the Principal Investigators for Gastro Health’s Liver studies with innovative trials for the treatment of Hepatitis B and C and NASH/NAFLD.
We hope the information provided will lend insight into the world of clinical research. However, if you have any questions or would like more information, please contact us at 513-872-4549.